Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

, DUK

Duke Energy

$76.57

-0.52 (-0.67%)

17:52
10/07/16
10/07
17:52
10/07/16
17:52

On The Fly: After Hours Movers

HIGHER: Mylan (MYL), up 11.2% after it agreed to a $465M settlement with the U.S. Department of Justice on its EpiPen Auto-Injector and cut its fiscal 2016 adjusted earnings per share guidance... Duke Energy (DUK), up 3.4% after its Florida subsidiary reported 162,800 power outages in the state as a result of Hurricane Matthew... CBS (CBS), up 0.3% after the Wall Street Journal reported that it and Viacom (VIA, VIAB) hired advisors for a potential combination. LOWER: Inotek Pharmaceuticals (ITEK), down 10.8% after it disclosed in a regulatory filing that it informed chief scientific officer William McVicar that his employment will be ending... Twilio (TWLO), down 3.6% after it filed to sell $400M of Class A common stock.

MYL

Mylan

$35.94

-0.9 (-2.44%)

DUK

Duke Energy

$76.57

-0.52 (-0.67%)

CBS

CBS

$55.22

-0.99 (-1.76%)

VIA

Viacom

$40.99

-0.38 (-0.92%)

VIAB

Viacom

$36.27

-0.35 (-0.96%)

ITEK

Inotek Pharmaceuticals

$9.02

-0.19 (-2.06%)

TWLO

Twilio

$60.58

-0.11 (-0.18%)

  • 07

    Oct

  • 03

    Nov

  • 04

    Nov

  • 07

    Nov

  • 14

    Nov

  • 08

    Dec

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

09/23/16
BERN
09/23/16
NO CHANGE
BERN
Mylan generic Epipen to lower EPS by about 10%, says Bernstein
Bernstein analyst Aaron Gal estimates that Mylan's decision to introduce a generic version of its EpiPen will create a drag of about 10% on its EPS. After viewing the Congressional hearings on the device, Gal continues to believe that a competitor to EpiPen will hit the market before the end of 2018. He keeps a $60 price target and Outperform rating on Mylan.
09/30/16
LEER
09/30/16
NO CHANGE
Target $45
LEER
Outperform
Mylan price target cut to $45 on lower EpiPen estimates at Leerink
Leerink analyst Jason Gerberry lowered his EpiPen sales forecasts by 33-45% from 2017-2021 in light of recent company updates, including its plan to launch an authorized generic of the emergency treatment later this year. While Mylan "appears on the right side of the law" regarding the latest Medicaid rebate controversy, Gerberry believes investors should consider the risk of a future settlement related to the issue. He cut his price target on Mylan shares to $45 from $55, but keeps an Outperform rating on the stock as he sees cash flows being sufficient to justify the current price.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan price target lowered to $52 from $62 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Mylan to $52 saying he remains cautious on the shares over the near-term given the ongoing Epipen controversy. The analyst, however, views the stock as "very inexpensive" and keeps an Overweight rating on the name. Schott sees a limited long-term impact to his thesis from the Epipen controversy and believes Mylan's generics business is underappreciated. He maintains an Overweight rating on the shares.
09/22/16
ARGS
09/22/16
NO CHANGE
ARGS
Mylan weakness creates good entry point, says Argus
After Mylan's stock fell 17% over the last month, Argus analyst Jacob Kilstein thinks that the stock has reached an attractive entry point, He says that the company's new generic EpiPen will cannibalize branded sales but should help it beat upcoming generic competitors. He thinks that the stock is undervalued and keeps a Buy rating on the stock.
DUK Duke Energy
$76.57

-0.52 (-0.67%)

02/19/16
02/19/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on the today's top five analyst downgrades with this list compiled by The Fly: 1. Best Buy (BBY) downgraded to Neutral at Goldman by analyst Matthew Frassler, who said that the strength in TV sales will be offset by a "sluggish" wireless market. 2. UPL Petroleum (UPL) double downgraded to Sell at KLR Group by analyst John Gerdes, who said the company's debt capitalization is no longer viable. 3. Trinity Industries (TRN) downgraded to Underweight at BB&T by analyst Thomas Albrecht, who expects a decline at the company's earnings outlook. Albrecht estimates tangible book value at $19.35 could attract some value investors, but does not see any catalysts to change the earnings outlook. 4. EP Energy (EPE) downgraded to Hold and Neutral at Topeka and UBS, respectively, with analysts citing balance sheet concerns and mixed Q4 results. Topeka analyst Gabriele Sorbara added that she does not see any near-term catalysts for an improvement in its leverage or outspend position as management may have missed its opportunity to sell/JV assets or issue equity. 5. Duke Energy (DUK) downgraded to Neutral at JPMorgan by analyst Christopher Turnure, who cited the company's "disappointing" core business outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/06/16
ARGS
04/06/16
DOWNGRADE
ARGS
Hold
Duke Energy downgraded to Hold from Buy at Argus
Argus downgraded Duke Energy to Hold based primarily on valuation.
02/22/16
UBSW
02/22/16
NO CHANGE
Target $82
UBSW
Buy
Duke Energy price target raised to $82 from $76 at UBS
UBS raised its price target on Duke Energy to $82 from $76 citing the planned sale of its Latin American assets as well as accretion from the acquisition of Piedmont and a higher multiple than peers due to a lower risk profile. UBS reiterated its Buy rating on Duke Energy shares.
02/19/16
WOLF
02/19/16
DOWNGRADE
WOLF
Underperform
Duke Energy downgraded to Underperform from Peer Perform at Wolfe Research
CBS CBS
$55.22

-0.99 (-1.76%)

09/22/16
09/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. CBS (CBS) downgraded to Market Perform from Outperform at Telsey Advisory with analyst Tom Eagan saying that CBS will probably merge with Viacom (VIA, VIAB). 2. Jabil Circuit (JBL) downgraded to Hold from Buy at Needham with analyst Sean Hannan saying that 2017 will unlikely be a "robust year." 3. Pearson (PSO) downgraded to Neutral from Outperform at Exane BNP Paribas. 4. Syntel (SYNT) downgraded to Market Perform from Outperform at Barrington with analyst Vincent Colicchio saying he's "increasingly concerned that the challenging environment will continue to negatively impact the company's business." 5. FMC Technologies (FTI) downgraded to Neutral from Accumulate at Seaport Global wit analyst Mark Brown saying upstream customers have "little appetite" for deepwater development spending. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/04/16
UBSW
10/04/16
UPGRADE
UBSW
Buy
CBS upgraded to Buy from Sell at UBS
10/04/16
UBSW
10/04/16
UPGRADE
Target $66
UBSW
Buy
CBS upgraded to Buy at UBS
As reported previously, UBS analyst Doug Mitchelson upgraded CBS (CBS) to Buy from Sell. The analyst sees any deal with Viacom (VIA) as priced into CBS shares already. He also has increased confidence in consensus estimates for CBS and sees further upside if the national TV ad market and CBS' ratings remain strong. Mitchelson raised his price target to $66 from $52 on CBS shares.
10/04/16
10/04/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. CBS (CBS) upgraded to Buy from Sell at UBS with analyst Doug Mitchelson saying he sees any deal with Viacom (VIA) as priced into CBS shares already. He also has increased confidence in consensus estimates for CBS and sees further upside if the national TV ad market and CBS' ratings remain strong. 2. Pandora (P) upgraded to Conviction Buy from Buy at Goldman with analyst Heath Terry saying he sees significant upside to out-year estimates from premium radio and on-demand subscriptions. He expects competition to ease as new entrants slow and existing providers focus on profitability and limit "free" models. 3. Las Vegas Sands (LVS) upgraded to Buy from Neutral at BofA/Merrill with analyst Shaun Kelley saying shares remain fairly under-owned and thinks estimate revisions will move higher due to market momentum, better ROI for Parisian, Cotai infrastructure additions, and optionality from Japan and real estate. 4. KBR (KBR) upgraded to Buy from Hold at Deutsche Bank with analyst Chad Dillard saying yesterday's 10% post-guidance cut selloff is overdone and backward-looking. 5. West Marine (WMAR) upgraded to Buy from Neutral at B. Riley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
VIA Viacom
$40.99

-0.38 (-0.92%)

09/22/16
TLSY
09/22/16
DOWNGRADE
TLSY
Market Perform
CBS downgraded on likely Viacom merger at Telsey Advisory
As noted earlier, Telsey downgraded CBS (CBS) to Market Perform from Outperform. Analyst Tom Eagan says that CBS will probably merge with Viacom (VIA, VIAB). The analyst believes that it will take "years" for Viacom to be turned around, and he says that Viacom's fiscal 2017 EBITDA will come in 18% below its fiscal 2015 level. The analyst expects the company's credit rating to be downgraded by S&P. CBS target to $57 from $67.
09/20/16
WELS
09/20/16
NO CHANGE
WELS
Viacom dividend likely to be eliminated, says Wells Fargo
Wells Fargo says that the market is expecting Viacom (VIA,VIAB) to cut its dividend by 50%. However, Wells Fargo says that the company will eliminate its entire dividend within tow months from now. The firm says that a 50% cut would enable Viacom to barely make its debt payments for the next year but still leave it "with limited financial visibility running at break-even with no cushion." The firm thinks that the company needs at least some cash cushion. It does not expect the company to merge with CBS (CBS) and keeps an Underperform rating on Viacom.
09/20/16
BMUR
09/20/16
NO CHANGE
Target $65
BMUR
Buy
Brean Capital says merger between Viacom and CBS is quite possible
Brean Capital analyst Alan Gould believes a merger between Viacom (VIA) and CBS (CBS) is quite possible. In such a scenario, the analyst sees Viacom buying CBS, which would allow for a greater premium to CBS shareholders, but he added there is also the possibility of CBS doing the buying. Gould believes a merger would be the best way to maximize returns for both shareholders. He also believes such a merger could already be discounted in the shares. Gould rates CBS a Buy with a $65 price target.
VIAB Viacom
$36.27

-0.35 (-0.96%)

09/21/16
WDLK
09/21/16
NO CHANGE
Target $65
WDLK
Viacom price target lowered to $65 from $82 at Wunderlich
09/22/16
FBCO
09/22/16
NO CHANGE
Target $42
FBCO
Outperform
Viacom price target lowered to $42 from $53 at Credit Suisse
Credit Suisse analsyt Omar Sheikh lowered Viacom estimates driven by lower forecasts for Paramount and reduced its price target to $42 from $53. The analyst believes management changes make the long-term earnings recovery from a potential restructuring of Cable Networks and a return of Paramount profitability more likely and maintains his Outperform rating.
ITEK Inotek Pharmaceuticals
$9.02

-0.19 (-2.06%)

09/20/16
HCWC
09/20/16
INITIATION
Target $22
HCWC
Buy
Inotek Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Inotek Pharmaceuticals with a Buy rating and $22 price target.
TWLO Twilio
$60.58

-0.11 (-0.18%)

08/25/16
08/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cree (CREE) initiated with a Buy at Roth Capital. 2. Reynolds American (RAI) initiated with a Neutral at UBS. 3. Twilio (TWLO) initiated with a Hold at Argus. 4. Phillips 66 Partners (PSXP) initiated with a Neutral at Goldman. 5. WD-40 (WDFC) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/16
ARGS
08/25/16
INITIATION
ARGS
Hold
Twilio initiated with a Hold at Argus
Argus analysts Stephen Biggar and Mike Jaffe say that Twilio's opportunists should increase significantly going forward, but they predict that it will report losses "for several more quarters." The analysts say that the stock appears to be "fully valued" at current levels.
07/18/16
07/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Twilio (TWLO) initiated with a Neutral at Goldman, an Outperform at William Blair, a Hold at Canaccord, a Sector Weight at Pacific Crest, a Market Perform at JMP Securities, and with a Neutral at JPMorgan. 2. Selecta Biosciences (SELB) initiated with a Buy at UBS, a Buy at Stifel, a Buy at Canaccord, and a Buy at Needham. 3. China Mobile (CHL) and China Telecom (CHA) assumed with a Buy at Jefferies. 4. NetEase (NTES) initiated with a Buy at Brean Capital. 5. Sysco (SYY) reinstated with a Hold at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/18/16
JPMS
07/18/16
INITIATION
Target $39
JPMS
Neutral
Twilio initiated with a Neutral at JPMorgan
JPMorgan analyst Mark Murphy started Twilio with a Neutral rating and $39 price target.

TODAY'S FREE FLY STORIES

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

, WMT

Wal-Mart

$75.59

0.75 (1.00%)

15:12
06/26/17
06/26
15:12
06/26/17
15:12
Recommendations
Quest Diagnostics, Wal-Mart analyst commentary  »

Raymond James positive on…

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

WMT

Wal-Mart

$75.59

0.75 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NOV

National Oilwell

$31.84

0.2 (0.63%)

15:10
06/26/17
06/26
15:10
06/26/17
15:10
Options
Notable call writing in National Oilwell »

Notable call writing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

VTR

Ventas

$71.94

0.215 (0.30%)

15:07
06/26/17
06/26
15:07
06/26/17
15:07
Conference/Events
Ventas management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MU

Micron

$32.50

0.765 (2.41%)

15:05
06/26/17
06/26
15:05
06/26/17
15:05
Options
Micron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

MAR

Marriott

$104.06

0.17 (0.16%)

15:00
06/26/17
06/26
15:00
06/26/17
15:00
Conference/Events
Marriott management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.92

1.38 (14.47%)

14:54
06/26/17
06/26
14:54
06/26/17
14:54
Periodicals
Apple only leasing six cars from Hertz, CNBC says »

After Bloomberg reported…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.92

1.38 (14.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NG

NovaGold

$4.50

-0.075 (-1.64%)

14:49
06/26/17
06/26
14:49
06/26/17
14:49
Options
NovaGold options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.84

1.3002 (13.63%)

14:47
06/26/17
06/26
14:47
06/26/17
14:47
Periodicals
Hertz to manage small self-driving car fleet for Apple, Bloomberg says »

Apple (AAPL) is leasing a…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.84

1.3002 (13.63%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

CAR

Avis Budget

$24.24

1.23 (5.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

OTIC

Otonomy

$18.75

1 (5.63%)

14:46
06/26/17
06/26
14:46
06/26/17
14:46
Conference/Events
Otonomy to hold a breakfast meeting »

Chief Scientific Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

, WMT

Wal-Mart

$75.61

0.77 (1.03%)

14:44
06/26/17
06/26
14:44
06/26/17
14:44
Hot Stocks
Quest Diagnostics, Wal-Mart team up to offer healthcare services »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

WMT

Wal-Mart

$75.61

0.77 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EBSB

Meridian Bancorp

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Upgrade
Meridian Bancorp rating change  »

Meridian Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$14.17

-0.21 (-1.46%)

, INTC

Intel

$34.19

-0.17 (-0.49%)

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Recommendations
AMD, Intel analyst commentary  »

Goldman reiterates Sell…

AMD

AMD

$14.17

-0.21 (-1.46%)

INTC

Intel

$34.19

-0.17 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Aug

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

, PRXL

Parexel

$86.80

-0.31 (-0.36%)

14:41
06/26/17
06/26
14:41
06/26/17
14:41
Hot Stocks
Kitov sees formal filing of NDA for KIT-302 by end of Q3 »

Kitov Pharmaceuticals…

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

RAD

Rite Aid

$3.93

0.8199 (26.36%)

14:40
06/26/17
06/26
14:40
06/26/17
14:40
Options
Heavy trading in RiteAid as shares surge »

Heavy trading in RiteAid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
06/26/17
06/26
14:40
06/26/17
14:40
General news
Treasury Action: yields remain slightly lower »

Treasury Action: yields…

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:39
06/26/17
06/26
14:39
06/26/17
14:39
Conference/Events
EVINE Live management to meet with Craig-Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:38
06/26/17
06/26
14:38
06/26/17
14:38
Conference/Events
EVINE Live management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

HTZ

Hertz

$10.19

0.65 (6.81%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Technical Analysis
Technical View: Hertz spikes higher, levels to watch »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Recommendations
AMAG Pharmaceuticals analyst commentary  »

AMAG delay for Makena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$45.60

5.58 (13.94%)

14:30
06/26/17
06/26
14:30
06/26/17
14:30
Options
Timely call activity in Fabrinet »

Timely call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 29

    Aug

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.24

0.7 (7.34%)

14:26
06/26/17
06/26
14:26
06/26/17
14:26
Periodicals
Breaking Periodicals news story on Apple, Hertz »

Hertz to manage small…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.24

0.7 (7.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GM

General Motors

$34.49

0.29 (0.85%)

14:25
06/26/17
06/26
14:25
06/26/17
14:25
Conference/Events
General Motors to host a conference call »

EVP & CFO Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

T

AT&T

$38.15

0.2001 (0.53%)

14:20
06/26/17
06/26
14:20
06/26/17
14:20
Options
Calendar call spread in AT&T rolls short position from July to September »

Calendar call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:19
06/26/17
06/26
14:19
06/26/17
14:19
General news
Averages mixed but internals strong »

The averages remain mixed…

$NSD

NASDAQ Market Internals

14:17
06/26/17
06/26
14:17
06/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.